Pharmaceutical Pricing and Reimbursement Systems in EU Member States
Overview of the talk <ul><li>1. Background </li></ul><ul><li>2. Pricing </li></ul><ul><li>3. Reimbursement </li></ul><ul><...
1. Background
Why is the pharmaceutical market uncertain? High cost of bringing drugs to market and high rates of failure Patent system ...
What tradeoffs do EU payers make in coverage decisions? Industrial  Policy Public  Policy
Industrial policy trade-off of jobs and economic growth.
Public policy trade-off of access, efficiency, and equity
2. Pricing
The three main approaches to  pricing  are: free pricing, direct price controls, and indirect price controls
Under   free pricing   manufacturers can price according to what the market will bear.
Direct price controls   force manufacturers to price at levels approved by the health system.   negotiated prices cost-plu...
Negotiated prices  are set in negotiations between the manufacturer and the government and based on a variety of factors.
Cost-plus pricing   is set by the cost of manufacturing a drug plus an additional percentage profit level.
Countries Lowest Original Country Lowest in EU In  international price comparisons ,  prices are based on a weighted avera...
Indirect price controls   incentivize manufacturers to keep prices within “acceptable” levels.  reference pricing rate-of-...
Reference pricing   sets a base price at which patients must pay out-of-pocket for excess costs above this price
Rate-of-return regulation The UK allows certain manufacturers to freely price drugs within profit limits
3. Reimbursement
The two main approaches to  reimbursement  are: listing and economic evaluation.
Positive (negative) lists   include (exclude) medicines for reimbursement.
Health economic evaluation ,  which weighs costs against benefits of treatments, now plays a greater role in reimbursement.
4. Concluding remarks
27 different pricing and reimbursement policies in the EU
Divergence in national pharmaceutical policies, but a trend toward health economic evaluation in coverage decisions
Photo credits <ul><li>Slide 7: padlock,  http://www.sxc.hu/browse.phtml?f=view&id=204785 </li></ul><ul><li>Slide 9: price ...
Upcoming SlideShare
Loading in...5
×

Rethink the Academic Talk - 2

1,030

Published on

I welcome your comments/suggestions! This presentation is not meant to be understood without the narrative - there is a lot of additional information the presenter would say verbally. I hope to show that academic presentations can be interesting, credible, and informative.

Published in: Education, Business, Technology
1 Comment
2 Likes
Statistics
Notes
  • Dear Marin,

    First of all, my compliments. You've done a very good job in both presentations.

    This comment values for both of your presentations.

    What I missed (maybe you told it verbally, anyway...):
    1 - Who are you?
    2 - What's the point? What am I going to learn?
    3 - A structured ending... 'a - You've learned that...', 'b - Thank you', 'c - Your name, email/phone'

    The design is very good in the whole. You chose a very clean layout, but, it seems to me that you had some trouble with slides like numbers 4, 5, 9. 11, 15 and 19. I think you could have found better ways to express the idea you wanted to convey with those slides.

    Keep up the good work!

    Best regards.
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
No Downloads
Views
Total Views
1,030
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
1
Likes
2
Embeds 0
No embeds

No notes for slide
  • Rethink the Academic Talk - 2

    1. 1. Pharmaceutical Pricing and Reimbursement Systems in EU Member States
    2. 2. Overview of the talk <ul><li>1. Background </li></ul><ul><li>2. Pricing </li></ul><ul><li>3. Reimbursement </li></ul><ul><li>4. Concluding remarks </li></ul>
    3. 3. 1. Background
    4. 4. Why is the pharmaceutical market uncertain? High cost of bringing drugs to market and high rates of failure Patent system confers monopoly rights What should be price of product? What is acceptable level of profit?
    5. 5. What tradeoffs do EU payers make in coverage decisions? Industrial Policy Public Policy
    6. 6. Industrial policy trade-off of jobs and economic growth.
    7. 7. Public policy trade-off of access, efficiency, and equity
    8. 8. 2. Pricing
    9. 9. The three main approaches to pricing are: free pricing, direct price controls, and indirect price controls
    10. 10. Under free pricing manufacturers can price according to what the market will bear.
    11. 11. Direct price controls force manufacturers to price at levels approved by the health system. negotiated prices cost-plus pricing international price comparisons
    12. 12. Negotiated prices are set in negotiations between the manufacturer and the government and based on a variety of factors.
    13. 13. Cost-plus pricing is set by the cost of manufacturing a drug plus an additional percentage profit level.
    14. 14. Countries Lowest Original Country Lowest in EU In international price comparisons , prices are based on a weighted average of prices from a basket of countries.
    15. 15. Indirect price controls incentivize manufacturers to keep prices within “acceptable” levels. reference pricing rate-of-return regulation
    16. 16. Reference pricing sets a base price at which patients must pay out-of-pocket for excess costs above this price
    17. 17. Rate-of-return regulation The UK allows certain manufacturers to freely price drugs within profit limits
    18. 18. 3. Reimbursement
    19. 19. The two main approaches to reimbursement are: listing and economic evaluation.
    20. 20. Positive (negative) lists include (exclude) medicines for reimbursement.
    21. 21. Health economic evaluation , which weighs costs against benefits of treatments, now plays a greater role in reimbursement.
    22. 22. 4. Concluding remarks
    23. 23. 27 different pricing and reimbursement policies in the EU
    24. 24. Divergence in national pharmaceutical policies, but a trend toward health economic evaluation in coverage decisions
    25. 25. Photo credits <ul><li>Slide 7: padlock, http://www.sxc.hu/browse.phtml?f=view&id=204785 </li></ul><ul><li>Slide 9: price tag, http://www.sxc.hu/photo/480217 </li></ul><ul><li>Slide 12: handshake, http://www.sxc.hu/browse.phtml?f=view&id=1065245 </li></ul><ul><li>Slide 16: building blocks, http://www.sxc.hu/photo/596909 </li></ul><ul><li>Slide 19: money exchange, http://www.sxc.hu/photo/577717 </li></ul><ul><li>Slide 20: pen, http:// www.sxc.hu/browse.phtml?f = view&id =921719 </li></ul><ul><li>Slide 23: pharmaceuticals, http://www.sxc.hu/browse.phtml?f=view&id=1028441 </li></ul><ul><li>Slide 24: pharmaceuticals, http://www.sxc.hu/photo/851433 </li></ul>

    ×